He explained that the site visit has covered the cannabis plantation procedure under the Department of Thai Traditional and Alternative Medicine, registration procedure under the Thai Food and Drug Administration, active ingredient extraction under the Department of Medical Sciences, and cannabis medical product use under the Department of Medical Services. The cannabis has also already registered as the national drug list for herb so patients under the health security system are able to access medical treatment with cannabis use.
If, he added, Malaysia can move forward for implementing cannabis policy of medical treatment, further mutual cannabis research and development for medical purpose is expected to happen.
Regarding GPO’s cannabis development, it successfully developed cannabis’s active ingredients for sublingual drops with four formulas, which is used for patients under the Department of Medical Services’ guidelines. They are intensive THC formula, 1:1 ratio between THC and CBD, THC FORTE with THC 81mg/ml for cancer patients with last stage of cancer disease, or patients suffering from severe vomit from chemotherapy treatment and finally the formula with intensive CBD for epilepsy in children.
Those have been already applied to cannabis clinics in 12 public health constituencies nationwide, which are later expanded into both state-owned and public hospitals. Moreover, the Department of Medical Services and other hospitals are going to have further cannabis use study in other diseases such as Parkinson’s disease and Multiple Sclerosis-MS. Latest, those four formulas are already under the national drug list for herb.